MX2009010870A - Vector adenoviral que codifica el antigeno de malaria. - Google Patents

Vector adenoviral que codifica el antigeno de malaria.

Info

Publication number
MX2009010870A
MX2009010870A MX2009010870A MX2009010870A MX2009010870A MX 2009010870 A MX2009010870 A MX 2009010870A MX 2009010870 A MX2009010870 A MX 2009010870A MX 2009010870 A MX2009010870 A MX 2009010870A MX 2009010870 A MX2009010870 A MX 2009010870A
Authority
MX
Mexico
Prior art keywords
adenoviral vector
vector encoding
malaria antigen
encoding malaria
antigen
Prior art date
Application number
MX2009010870A
Other languages
English (en)
Inventor
Riccardo Cortese
Arturo Reyes
Adrian Hill
Geraldine O Hara
Stefano Colloca
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Publication of MX2009010870A publication Critical patent/MX2009010870A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención proporciona vectores adenovirales recombinantes que son capaces de generar inmunidad contra la etapa pre-eritrocítica del ciclo de vida del parásito de la malaria. En particular, la invención proporciona un vector adenoviral de simio, deficiente en la replicación, recombinante, que codifica un antígeno que comprende la proteína de adhesión relacionada con la trombospondina (TRAP), y también las composiciones inmunogénicas (por ejemplo, vacunas) que comprenden el vector y los métodos de uso de tales composiciones.
MX2009010870A 2007-04-10 2008-04-10 Vector adenoviral que codifica el antigeno de malaria. MX2009010870A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0706914A GB0706914D0 (en) 2007-04-10 2007-04-10 Novel adenovirus vectors
GB0717888A GB0717888D0 (en) 2007-04-10 2007-09-13 Adenoviral vector encoding malaria antigen
PCT/GB2008/001175 WO2008122769A2 (en) 2007-04-10 2008-04-10 Adenoviral vector encoding malaria antigen

Publications (1)

Publication Number Publication Date
MX2009010870A true MX2009010870A (es) 2010-02-17

Family

ID=38091120

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010870A MX2009010870A (es) 2007-04-10 2008-04-10 Vector adenoviral que codifica el antigeno de malaria.

Country Status (11)

Country Link
US (3) US9895431B1 (es)
EP (3) EP2160197B1 (es)
JP (1) JP5505937B2 (es)
CN (1) CN101848729A (es)
AU (1) AU2008235363B2 (es)
BR (1) BRPI0810163A2 (es)
CA (1) CA2683679A1 (es)
ES (2) ES2638577T3 (es)
GB (2) GB0706914D0 (es)
MX (1) MX2009010870A (es)
WO (2) WO2008122811A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
EP2137210B1 (en) * 2007-03-02 2016-10-19 GlaxoSmithKline Biologicals SA Novel method and compositions
WO2009071613A2 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Vaccine
GB0823497D0 (en) * 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
US20110104195A1 (en) * 2009-11-05 2011-05-05 Joao Aguiar Plasmodium falciparum sporozoite and liver stage antigens
WO2014005643A1 (en) * 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
CN103923943B (zh) * 2013-08-19 2019-01-22 中国科学院上海巴斯德研究所 一种基于腺病毒AdC7的表达载体及其构建方法
PL3062815T3 (pl) 2013-11-01 2019-07-31 Pfizer Inc. Wektory do ekspresji antygenów związanych z gruczołem krokowym
EP3888676A1 (en) 2014-06-13 2021-10-06 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
MX2017016105A (es) * 2015-06-12 2018-05-15 Glaxosmithkline Biologicals Sa Polinucleotidos y polipeptidos de adenovirus.
CN109803676A (zh) * 2016-04-12 2019-05-24 牛津大学创新有限公司 初免靶向
AU2017305176B2 (en) * 2016-08-01 2021-05-27 The Wistar Institute Of Anatomy And Biology Compositions and methods of replication deficient adenoviral vectors for vaccine applications
WO2018208856A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
KR20200118029A (ko) 2018-01-04 2020-10-14 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
GB201818084D0 (en) 2018-11-06 2018-12-19 Univ Oxford Innovation Ltd Compositions and methods
TW202110870A (zh) 2019-05-30 2021-03-16 美商葛利史東腫瘤科技公司 經修飾之腺病毒
CA3171939A1 (en) 2020-03-13 2021-09-16 Oxford University Innovation Limited Compositions and methods for inducing an immune response
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
WO2022056488A1 (en) * 2020-09-14 2022-03-17 Genprex, Inc. Nonviral vectors for increasing fas expression in cancer cells and methods of use thereof
GB202016604D0 (en) 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
WO2022234283A1 (en) 2021-05-07 2022-11-10 Astrazeneca Uk Limited Compositions and methods for inducing an immune response

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018616A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2378539A1 (en) * 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
GB9922361D0 (en) 1999-09-21 1999-11-24 Isis Innovation Generating an immune response to an antigen
US8071322B2 (en) * 2002-11-12 2011-12-06 Epitomics, Inc. Method for identifying differentially expressed proteins
CA2519475A1 (en) 2003-03-14 2004-09-30 Merck & Co., Inc. Bicyclic anilide spirohydantoin cgrp receptor antagonists
CA2553541C (en) * 2004-01-23 2015-04-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Chimpanzee adenovirus vaccine carriers
CA2579221A1 (en) 2004-09-08 2006-03-16 Merck & Co., Inc. Monocyclic anilide spirolactam cgrp receptor antagonists
US8099179B2 (en) 2004-09-10 2012-01-17 GM Global Technology Operations LLC Fault tolerant control system
CA2620495A1 (en) * 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
AP2580A (en) * 2005-11-08 2013-01-30 South African Medical Res Council Expression system incorporating a capsid promoter sequence as an enhancer
KR20090034297A (ko) 2006-02-16 2009-04-07 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 인플루엔자에 대한 항바이러스제 및 백신
EP2024358B1 (en) 2006-05-09 2014-11-05 Merck Sharp & Dohme Corp. Substituted spirocyclic cgrp receptor antagonists
WO2008112159A2 (en) 2007-03-12 2008-09-18 Merck & Co., Inc. Monocyclic anilide spirolactam cgrp receptor antagonists

Also Published As

Publication number Publication date
US9017696B2 (en) 2015-04-28
US10124048B2 (en) 2018-11-13
JP5505937B2 (ja) 2014-05-28
EP2160197B1 (en) 2016-09-21
AU2008235363B2 (en) 2013-05-16
US20150297700A1 (en) 2015-10-22
WO2008122811A2 (en) 2008-10-16
ES2606365T3 (es) 2017-03-23
EP2160197A2 (en) 2010-03-10
JP2010523137A (ja) 2010-07-15
EP2176418B1 (en) 2017-08-16
GB0717888D0 (en) 2007-10-24
WO2008122811A3 (en) 2009-01-22
EP2486939A1 (en) 2012-08-15
WO2008122769A2 (en) 2008-10-16
US9895431B1 (en) 2018-02-20
ES2638577T3 (es) 2017-10-23
GB0706914D0 (en) 2007-05-16
US20120058138A1 (en) 2012-03-08
BRPI0810163A2 (pt) 2015-01-06
EP2486939B1 (en) 2017-07-12
CA2683679A1 (en) 2008-10-16
EP2176418A2 (en) 2010-04-21
AU2008235363A1 (en) 2008-10-16
CN101848729A (zh) 2010-09-29
WO2008122769A3 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
MX2009010870A (es) Vector adenoviral que codifica el antigeno de malaria.
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
IL182357A0 (en) Malaria prime/boost vaccines
WO2006036550A3 (en) Listeria-based and llo-based vaccines
TW200621287A (en) Vaccines
MX2009009342A (es) Metodo novedoso y composiciones.
IN2012DN02368A (es)
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
MX2014009845A (es) Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos.
WO2008140812A3 (en) Compositions and methods comprising klk3, psca, or folh1 antigen
WO2007041216A3 (en) Plasmodium liver stage antigens
UA97092C2 (ru) T-клеточные эпитопы с раково-эмбрионального антиген-незрелого рецепторного белка ламинина и их медицинское применение
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
WO2007008527A3 (en) Chimeric vaccine for haemophilus influenzae-induced disease
MX2009007572A (es) Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
MX2009003679A (es) Composicion de adn para provocar una respuesta inmune contra los macrofagos asociados a tumores.
MX354752B (es) Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
WO2008086386A8 (en) Adenoviral vector-based malaria vaccines
DK1599225T3 (da) Sammensætninger og fremgangsmåder til frembringelsen af beskyttende immunrespons mod malaria
WO2007020520A3 (en) Antigenic peptides and their use
PH12018502430A1 (en) Vaccines
WO2020074908A3 (en) Treatment and prevention of malaria based on the antigen pfrh5 and antibodies against the same
WO2007127372A3 (en) Genetic adjuvants for viral vaccines
GB0510763D0 (en) Malaria vaccines

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration